Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 14 04:00PM ET
15.30
Dollar change
+0.18
Percentage change
1.19
%
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y8.46% Shs Outstand Perf Week6.80%
SponsorAdvisor Shares ETF Type Tagsequity Return% 3Y-31.36% Total Holdings27 Perf Month20.33%
Fund Family Bond Type Tagshealthcare Return% 5Y- AUM11.02M Perf Quarter17.69%
Index- Average Maturity Tagspharmaceutical Return% 10Y NAV% Perf Half Y75.16%
Index Weighting Commodity Type Tagsmedical Return% SI NAV/sh Perf Year6.99%
Active/Passive Quant Type Tags- Flows% 1M22.77% 52W Range7.14 - 17.00 Perf YTD39.33%
Dividend TTM0.16 (1.07%) ESG Type Tags- Flows% 3M29.10% 52W High-10.00% Beta0.81
Dividend Ex-DateDec 23, 2024 Dividend Type Sector/Theme Flows% YTD25.35% 52W Low114.29% ATR (14)0.56
Expense0.99% Structure Type Region Flows% 1Y RSI (14)66.90 Volatility3.13% 3.27%
Option/ShortYes / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume2.40 Prev Close15.12
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume15.89K Price15.30
SMA2012.02% SMA5024.22% SMA20039.25% Trades Volume38,114 Change1.19%
AdvisorShares Psychedelics ETF seeks long-term capital appreciation. The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.